| abstract |
The present invention relates to immunosupplementants for novel vaccines, more specifically comprising IL-12 and IL-21 proteins as active ingredients, or polynucleotides encoding said IL-12 protein and said. It relates to an immunoadjuvant for a T lymphocyte-specific immune response-promoting vaccine containing a polynucleotide encoding the IL-21 protein as an active ingredient. |